Cagent Vascular announces initial RECOIL Study results

Serranator demonstrates 49% less recoil than POBA in BTK arteries BUSINESS WIRE: July 11, 2023. (Wayne, PA) Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA).